- Home
- NVCR vs AMPH Comparison
NVCR vs AMPH Comparison
Compare NVCR & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- AMPH
- Stock Information
- Founded
- NVCR 2000
- AMPH 1996
- Country
- NVCR Switzerland
- AMPH United States
- Employees
- NVCR N/A
- AMPH N/A
- Industry
- NVCR Medical/Dental Instruments
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- AMPH Health Care
- Exchange
- NVCR Nasdaq
- AMPH Nasdaq
- Market Cap
- NVCR 1.9B
- AMPH 1.1B
- IPO Year
- NVCR 2015
- AMPH 2014
- Fundamental
- Price
- NVCR $17.60
- AMPH $21.70
- Analyst Decision
- NVCR Buy
- AMPH Hold
- Analyst Count
- NVCR 7
- AMPH 5
- Target Price
- NVCR $32.43
- AMPH $38.00
- AVG Volume (30 Days)
- NVCR 1.4M
- AMPH 488.2K
- Earning Date
- NVCR 07-24-2025
- AMPH 08-06-2025
- Dividend Yield
- NVCR N/A
- AMPH N/A
- EPS Growth
- NVCR N/A
- AMPH N/A
- EPS
- NVCR N/A
- AMPH 2.77
- Revenue
- NVCR $621,711,000.00
- AMPH $730,659,000.00
- Revenue This Year
- NVCR $5.56
- AMPH $0.67
- Revenue Next Year
- NVCR $9.19
- AMPH $5.18
- P/E Ratio
- NVCR N/A
- AMPH $8.03
- Revenue Growth
- NVCR 18.27
- AMPH 8.05
- 52 Week Low
- NVCR $14.17
- AMPH $21.48
- 52 Week High
- NVCR $34.13
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- NVCR 49.74
- AMPH 28.01
- Support Level
- NVCR $16.81
- AMPH $22.81
- Resistance Level
- NVCR $18.59
- AMPH $23.77
- Average True Range (ATR)
- NVCR 0.74
- AMPH 0.76
- MACD
- NVCR 0.08
- AMPH -0.20
- Stochastic Oscillator
- NVCR 56.18
- AMPH 9.27
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.